Safety and Efficacy of Ponatinib for Pulmonary Tumor Thrombotic Microangiopathy
Background: We evaluated the safety and efficacy of ponatinib, a multi-target tyrosine kinase inhibitor, for pulmonary tumor thrombotic microangiopathy (PTTM).
Authors
- Yoshiyuki Yamamoto (ORCID: https://orcid.org/0000-0002-2932-5904)
- Tatsuhiro Sakamoto (ORCID: https://orcid.org/0000-0001-6852-0721)
- Ikuo Sekine (ORCID: https://orcid.org/0000-0003-1105-7339)
- Naoto Kawamatsu (ORCID: https://orcid.org/0000-0001-8533-1578)
- Masato Homma (ORCID: https://orcid.org/0000-0002-4824-3242)
- K Sato
- Tomoko Machino-Ohtsuka
- Masayoshi Yamamoto
- Tomoko Ishizu
- Takeshi Yamada
- Bryan J. Mathis
Institutions
- University of Tsukuba (JP)
Publication Details
- Journal
- Circulation Reports
- Published
- 2026-08-27
- DOI
- https://doi.org/10.1253/circrep.cr-26-0218
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Tsukuba